Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Titel:
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
Auteur:
Sezer, Ahmet Kilickap, Saadettin Gümüş, Mahmut Bondarenko, Igor Özgüroğlu, Mustafa Gogishvili, Miranda Turk, Haci M Cicin, Irfan Bentsion, Dmitry Gladkov, Oleg Clingan, Philip Sriuranpong, Virote Rizvi, Naiyer Gao, Bo Li, Siyu Lee, Sue McGuire, Kristina Chen, Chieh-I Makharadze, Tamta Paydas, Semra Nechaeva, Marina Seebach, Frank Weinreich, David M Yancopoulos, George D Gullo, Giuseppe Lowy, Israel Rietschel, Petra